IGFBP2 and lung carcinoma: Through in vitro and in vivo experiments, we demonstrated that the upregulation or downregulation of IGFBP2 significantly increased or decreased gefitinib resistance in lung cancer cells, accompanied by the induction of the epithelial-mesenchymal transition (EMT) in these cells.